Current state of, prospects for, and obstacles to mRNA vaccine development
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved..
Given their superior efficacy, rapid engineering, low-cost manufacturing, and safe delivery prospects, mRNA vaccines offer an intriguing alternative to conventional vaccination technologies. Several mRNA vaccine platforms targeting infectious diseases and various types of cancer have exhibited beneficial results both in vivo and in vitro. Issues related to mRNA stability and immunogenicity have been addressed. Current mRNA vaccines can generate robust immune responses, without being constrained by the major histocompatibility complex (MHC) haplotype of the recipient. Given that mRNA vaccinations are the only transient genetic information carriers, they are also safe. In this review, we provide an update and overview on mRNA vaccines, including their current state, and the problems that have prevented them from being used in more general therapeutic ways.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Drug discovery today - 28(2023), 2 vom: 31. Feb., Seite 103458 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aljabali, Alaa A A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Formulations |
|---|
| Anmerkungen: |
Date Completed 02.02.2023 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.drudis.2022.103458 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349407312 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349407312 | ||
| 003 | DE-627 | ||
| 005 | 20231227131017.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drudis.2022.103458 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM349407312 | ||
| 035 | |a (NLM)36427779 | ||
| 035 | |a (PII)S1359-6446(22)00451-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aljabali, Alaa A A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current state of, prospects for, and obstacles to mRNA vaccine development |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2023 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a Given their superior efficacy, rapid engineering, low-cost manufacturing, and safe delivery prospects, mRNA vaccines offer an intriguing alternative to conventional vaccination technologies. Several mRNA vaccine platforms targeting infectious diseases and various types of cancer have exhibited beneficial results both in vivo and in vitro. Issues related to mRNA stability and immunogenicity have been addressed. Current mRNA vaccines can generate robust immune responses, without being constrained by the major histocompatibility complex (MHC) haplotype of the recipient. Given that mRNA vaccinations are the only transient genetic information carriers, they are also safe. In this review, we provide an update and overview on mRNA vaccines, including their current state, and the problems that have prevented them from being used in more general therapeutic ways | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Formulations | |
| 650 | 4 | |a Vaccines | |
| 650 | 4 | |a mRNA | |
| 650 | 4 | |a mRNA design | |
| 650 | 4 | |a nanomaterials | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 700 | 1 | |a Bashatwah, Rasha M |e verfasserin |4 aut | |
| 700 | 1 | |a Obeid, Mohammad A |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Mishra, Yachana |e verfasserin |4 aut | |
| 700 | 1 | |a Serrano-Aroca, Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Lundstrom, Kenneth |e verfasserin |4 aut | |
| 700 | 1 | |a Tambuwala, Murtaza M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug discovery today |d 1998 |g 28(2023), 2 vom: 31. Feb., Seite 103458 |w (DE-627)NLM095449159 |x 1878-5832 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:2 |g day:31 |g month:02 |g pages:103458 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.drudis.2022.103458 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 2 |b 31 |c 02 |h 103458 | ||